| Dr Kim Loren Schmaltz, ND, DC | |
|
8855 Sw Holly Lane, Suite 105, Wilsonville, OR 97070 | |
| (503) 855-3244 | |
| (503) 855-3597 |
| Full Name | Dr Kim Loren Schmaltz |
|---|---|
| Gender | Male |
| Speciality | Naturopath |
| Location | 8855 Sw Holly Lane, Wilsonville, Oregon |
| Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255338273 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | 273050 (Oregon) | Secondary |
| 111N00000X | Chiropractor | 3050 (Oregon) | Secondary |
| 175F00000X | Naturopath | 1224 (Oregon) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Dr Kim Loren Schmaltz, ND, DC Po Box 2086, Wilsonville, OR 97070-2086 Ph: (503) 855-3244 | Dr Kim Loren Schmaltz, ND, DC 8855 Sw Holly Lane, Suite 105, Wilsonville, OR 97070 Ph: (503) 855-3244 |
News Archive
Five percent more cardiac infarctions detected and 11 percent fewer patients suffering a relapse. That is the result of a study of more than 80,000 patients in which two cardiac damage markers were compared with each other.
The dental profession needs to build a stronger connection between oral health and general health—not only for individual patients, but also at the community level, according to the special June issue of The Journal of Evidence-Based Dental Practice (JEBDP), the foremost publication of information about evidence-based dental practice, published by Elsevier.
MabCure, Inc., a biotechnology company that has developed a series of highly specific monoclonal antibodies (MAbs) to combat various types of cancers, has reached another development milestone, with the creation of its MAbs against Colorectal Cancer (CRC). After further characterization the company plans to explore the utility of these MAbs in terms of both the early diagnosis of CRC (in blood or feces specimens), as well as imaging agents for detecting micrometastatic disease during surgery and the detection of cancerous polyps during colonoscopy.
Each year, more than one thousand Norwegians develop lymphoma. A statistical genetic analysis can detect when the disease will be aggressive. Thereby, treatment can be initiated in time.
Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it received a complaint filed by Celgene Corporation seeking a declaration from the court that four Cyclacel-owned patents, which claim the use of romidepsin injection in T-cell lymphomas, are not infringed by Celgene's products and are invalid.
› Verified 8 days ago